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ABSTRACT
Quinolinol-based compounds are a promising starting point for discovery o f effective inhibitors 
o f the clostridial neurotoxin, botulinum neurotoxin type A light chain (BoNT/A LC). Insights 
into the mechanism o f inhibition by quinolinol compounds facilitate interpretation o f docking 
data and inhibitor optimization. In this study, a fluorogenic substrate o f BoNT/A, SNAPtide, was 
used to study the mechanism by which two new quinolinol compounds, MSU58 and M SU84, 
with IC50 values o f 3.3 pM  and 5.8 pM , respectively, inhibit BoNT/A LC. Kinetic studies and 
model discrimination analysis showed both compounds to be competitive inhibitors o f  BoNT/A 
LC with inhibition constants (Kj) 3.2 pM  and 6.2 pM  for MSU58 and MSU84, respectively. The 
kinetic rate constant for substrate and inhibitor binding and release were also determined. These 
data indicate that the inhibitors bind in the BoNT/A LC active site and that inhibitor binding is 
mutually exclusive with the binding o f the substrate. This is the first study to report the 
competitive inhibition o f BoNT/A LC by quinolinol compounds. These data help define the 
inhibitor binding pocket and, along with structure activity relationship studies, provide 
immediate direction for further compound synthesis.
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CHAPTER 1: INTRODUCTION
Botulinum neurotoxins (BoNTs) cause botulism, a deadly condition characterized by 
flaccid paralysis. They have been categorized as Category A biowarfare agents by the 
Centers o f Disease Control and Prevention f1'2]. While worldwide there are only about 
1000 cases reported yearly [3‘4], due to BoN T’s potency and potential ease o f  production 
for bioterrorism activity, inhibitors are needed for the clinic [4'9]. Current therapy for 
exposure to the toxin relies on inhibitory antibodies, which have several limitations 
including a limited supply o f the antitoxin, unknown long term effects, and a short 
application window (approximately 24 hours post exposure) [4'5>10]. Challenges in BoNT 
inhibitor discovery include the large peptide substrate-enzyme interface, which makes it 
more difficult to define a site where an inhibitor may bind, and conformational flexibility 
o f BoNT [4’ H]. Quinolinol compounds have been explored as BoNT inhibitors and 
optimization efforts can be aided by a deeper understanding o f the mechanism by which 
compounds inhibit BoNT activity.
BoNTs are produced by the anaerobic bacterium Clostridium botulinum and are 
endoproteases that cause flaccid neuromuscular paralysis by blocking acetylcholine 
release at the neuromuscular junction. BoNTs are secreted as holotoxins, consisting o f a 
-1 0 0  kD heavy chain (HC) and a -5 0  kD light chain (LC), linked by a disulfide bond [12~ 
14] (Figure 1). The LC is a zinc-dependent metalloprotease while the HC facilitates the 
targeting and internalization o f LC into cells [14]. There are seven antigenically distinct 
serotypes o f BoNTs labelled A-G; serotype A is the most potent and most prevalent toxin 
in humans [10,15]. When BoNT enters the bloodstream, the holotoxin is transported to the 
neurotransmitter junction and enters the presynaptic neuron. The LC is liberated
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intracellularly and cleaves soluble N-ethylmaleimide-sensitive fusion attachment protein 
receptor (SNARE) peptides and prevents acetylcholine release into the neuromuscular 
junction, resulting in neuromuscular paralysis (botulism) [10]. Intoxication with 
botulinum toxins may occur naturally through ingestion o f contaminated food (foodbome 
botulism), through wounds contaminated with clostridia, or by deliberate introduction 
through injection or inhalation [7].
FIGURE 1: Crystal structure of BoNT/A showing the 100 kD HC (green), 50 kD LC (blue, 
cyan), the receptor binding domain (yellow, red orange) and the catalytic zinc (dark grey). The 
crystal structure was obtained from the Protein Data Bank (PDB # 3BTA) and modified with 
Chimera (UCSF, San Francisco, CA).
The natural substrate o f BoNT/A is a large 25 kDa peptide (SNAP-25, amino acid 
residues 1-206) [ l5' 16]. Studies have shown that although the presence o f  the entire length 
o f the natural substrate enhances substrate recognition and specificity, only the amino 
acid residues 197-202 are in direct contact with the catalytic site o f BoNT/A LC.
Catalytic cleavage occurs at the scissile bond between residues 197 and 198 [2> l6]. Crystal 
structures o f truncated substrate analogs (aa residues 197-202) bound to BoNT/A LC
2
(PDB ID # 3DDA, 3DDB) revealed multiple potential sub-binding sites (subsites) in the 
active site [2]. The crystal structure # 3DDA shows that the carbonyl oxygen and N- 
terminal N H 2 o f G lnl97 o f the substrate chelate the catalytic zinc in the BoNT/A LC 
active site. The 8-hydroxyquinoline (quinolinol moiety) was suggested to form a close 
interaction with the zinc cation to exclude any water present at the active site [9’ I7], 
possibly mimicking the interaction between Gin 197 o f the substrate with the catalytic 
zinc. The salt bridge formed between the guanidinium o f A rgl98 sidechain and Asp370 
sidechain (BoNT/A LC residue) also appears to be crucial for catalytic activity [2]. 
Burnett and coworkers suggested that there are two binding subsites (1 and 2) in the 
catalytic region o f BoNT/A LC that are important for the proper binding and orientation 
o f  small molecule inhibitors. The hydrophobic pocket o f subsite 1 is occupied by the 
aromatic sidechains Phel62 , Phel77  and Phel93 and the methyl side chain o f Thr219. 
Hydrophobic interactions with a methyl substituent o f a chemical compound are typical 
interactions found in this site [9]. Subsite 2 is a deep pocket and consists o f  M etl64, 
T hrl75, Arg230, Pro238 and His226, which is required for catalysis. Several polar 
residues, Glu55, G lnl61, G lul63, Lysl75 and A rgl76, are also present in subsite 2 and 
may participate in ionic interactions or water mediated hydrogen bonding with an 
ionizable amine in an inhibitor [9]. Burnett and coworkers proposed that potent inhibitors 
o f BoNT/A LC must interact with residues present in both binding subsites 1 and 2 in the 
substrate binding region [9].
Efforts in small molecule and peptidic BoNT type A (BoNT/A) inhibitor 
discovery have been ongoing since the late 1990’s [8"9,13,18]. Silhar and coworkers 
reported that a hydroxamate compound used in combination with the non-competitive
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natural product inhibitor chicoric acid resulted in synergistic inhibition o f  BoNT/A LC 
but hydroxamate compounds raise toxicity concerns due to promiscuous zinc chelation 
[19,2°] Recentiy? quinolinol compounds have received attention as inhibitors o f  BoNT/A 
LC [4> 17,21] in part because o f structural dissimilarity to other known metalloprotease 
inhibitors. Moreover, quinolinol compounds have low molecular weights, offer several 
points for structure activity investigation and can be readily synthesized by a 
multicomponent condensation [17]. Caglic and coworkers screened 188 quinolinol 
compounds for inhibitory activity against BoNT/A LC and found that 80 % o f  the most 
active compounds had IC50 values below 10 pM  with few in the sub-micromolar range 
[17]. Structure activity relationship studies revealed that the quinolinol moiety alone was 
not sufficient to elicit any inhibitory activity against BoNT/A LC. Their analysis and 
modeling led to the hypothesis that aryl groups at R 2 and R3 o f the template (Figure 2) 
promote proper conformation, permit binding into the active site and that substitutions at 
positions R2 and R3 (Figure 2) with bulky heterocyclic groups improved inhibitory
activity [17]. However, no detailed enzymatic or kinetic studies were carried out to 
investigate the mechanism by which quinolinols inhibit BoNT/A.
FIGURE 2: Structures of the quinolinol scaffold (left) and compounds 4-chloro- A-[(4- 
fluorophenyl) methyl] pyridin-3-amine (MSU58) and 4-chloro-(3-fluorophenyl) methyl 
benzenesulfonamide (MSU84) (right).
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There are three types o f inhibition (competitive, noncompetitive, and 
uncompetitive) that are used to describe how an inhibitor binds to the target enzyme. 
Characterization o f the mechanism o f inhibition o f BoNT/A LC by quinolinol 
compounds can provide insights on how these compounds interact with the target. For 
example, knowing whether inhibitor and substrate binding are mutually exclusive events 
and whether an inhibitor binds in the substrate binding site or another distinct site would 
facilitate structure activity relationship studies, the design o f more potent inhibitors, and 
the interpretation o f inhibitory data. This understanding is particularly needed for 
BoNT/A LC, a challenging target with an unusually large substrate-enzyme interface 
where a small molecule may need to possess multiple functionalities to block the binding 
o f substrate. Molecular docking studies performed by Roxas-Duncan and coworkers with 
five quinolinol analogs predicted that they interact with the zinc cation in the 
hydrophobic pocket o f the LC, blocking the active site [4], Conversely, subsequent 
enzyme binding studies by Lai and coworkers reported noncompetitive inhibition o f 
BoNT/A LC by quinolinol compound 7-(phenyl(8-quinolinylamino) methyl)-8-quinolinol 
(QAQ) [21], Noncompetitive inhibitors bind to a site distinctly different from the substrate 
binding site and bind equally well to free enzyme and to enzyme-substrate complex. 
Optimization efforts o f noncompetitive inhibitors must focus on the site where the 
inhibitor binds, distinct from the substrate binding site, and consider the structural 
changes that result from substrate binding.
In this work, we determine the inhibition mechanisms o f two novel quinolinol 
inhibitors MSU58 and MSU84 (Figure 2) against BoNT/A LC metalloprotease activity 
using a commercially available fluorescent resonance energy transfer (FRET) substrate,
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SNAPtide. W hile the docking studies with several quinolinol inhibitors suggest that these 
compounds block the active site zinc, experimental kinetic studies on QAQ support 
noncompetitive inhibition. To increase the understanding o f the mechanism o f  action o f 
quinolinol derivatives against BoNT/A LC, we apply the FIQ correction and determine 
the mechanism o f inhibition by new compounds, MSU58 and MSU84.
CHAPTER 2: METHODS AND MATERIALS
Materials
A recombinant BoNT/A LC (product #610) (residues 1- 429 o f the full length BoNT/A), 
its fluorogenic substrate SNAPtide (FITC/DABCYL) (product #521) and the unquenched 
peptide (product #528) were obtained from List Biological Laboratories (Campbell, CA). 
The inhibitors, MSU58 and MSU84 were synthesized in the M ontclair State University 
medicinal chemistry laboratory. All other buffers and reagents were obtained from Fisher 
Scientific (Hampton, NH).
Preparation o f buffers, substrate (SNAPtide), enzyme (BoNT/A LC) and unquenched 
product
Enzyme dilution buffer (50 mM  K-HEPES with 0.05 % Tween 20, pH 7.4) and 
assay buffer (40 mM K-HEPES 0.01 % Tween 20, pH 7.4), were made from the free acid 
form o f HEPES (H-HEPES) and potassium-HEPES (K-HEPES). Each buffer solution 
was filter sterilized using a Coming 0.22 pM  filter and refrigerated. A 2.5 mM  stock 
solution o f  SNAPtide was prepared by reconstituting 200 nmoles o f the commercial 
product in 80% DMSO and a 2 pM  stock solution o f BoNT/A LC, by reconstituting 10
6
pg in enzyme dilution buffer, per m anufacturer’s instructions. The unquenched peptide 
(50 nmoles) was reconstituted in DMSO to make a 500 pM  stock solution. All the 
solutions were stored in aliquots at -20 °C and all assays were conducted in 40 mM  K- 
HEPES 0.01 % Tween 20 pH 7.4 at room temperature unless otherwise stated.
Determination o f kinetic parameters
The kinetic parameters and standard curves were measured concurrently in Costar half 
area black 96 well plates (Costar #3694, Coming Inc). The fluorescent signal was 
monitored in a Biotek (Synergy H I, # 15061913) plate reader set (490 nm excitation, 523 
nm emission; gain (sensitivity) o f 50) for 90 minutes at 1 minute intervals with shaking 
for 30 seconds between each read [22]. Unquenched peptide was diluted in assay buffer to 
final concentrations ranging from 0.3 pM  to 3 pM  to obtain a standard curve. The slope 
o f  the graph o f fluorescent signal versus concentration o f the unquenched peptide was 
used to convert the fluorescent signals o f the assay wells to initial velocities (V0) in 
pM/min.
The V0 measurements were conducted in triplicate at different substrate 
concentrations, with maximum substrate concentration o f 50 pM, in a 50 pL well volume 
containing 4.2 nM BoNT/A LC. Diluted substrate solutions were prepared in 16 % 
DMSO in assay buffer and each substrate solution contributed 1.6 % DM SO to the well. 
The final concentration o f  DMSO in the well was 3.2 % (1.6 % from SNAPtide and 1.6 
% from inhibitor). Control experiments demonstrated that BoNT/A LC could tolerate 
increasing DMSO concentrations up to 6 % DMSO in assay buffer with no significant 
reduction in reaction rate.
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Determination o f inhibition constants (Kj) and dissociation constant (KD)
The Kj o f MSU58 and MSU84 was determined using concentrations o f 0, 3, 6 and 
9 pM  o f each inhibitor. A 10 mM stock o f inhibitor was initially diluted in DMSO and 
then subsequently in assay buffer to make a 90 pM  inhibitor solution. Serial dilutions 
were made in 16 % DM SO in assay buffer and each inhibitor dilution contributed a final 
DMSO concentration o f 1.6 % in a 50 pL final assay volume containing 4.2 nM BoNT/A 
LC and multiple SNAPtide concentrations ranging from 2.9 ¡iM to 50 pM.
The inhibitor, assay buffer and BoNT/A LC were preincubated for 30 minutes on 
a plate shaker at room temperature after which the SNAPtide was added and placed in the 
Synergy H I plate reader for a kinetic read. Controls for the assay include, BoNT/A LC 
and SNAPtide in the absence o f inhibitor, SNAPtide alone, assay buffer alone and the 
unquenched peptide at varying concentrations. The reciprocals o f the VQwere plotted 
against the inhibitor concentration to form Dixon plots, from which the Kj values were 
estimated. The Kj values were also determined from the IC50 values, using the Cheng- 
Prusoff equation [23].
To determine the KD the fluorescence o f BoNT/A LC (0.2 pM) in 250 pL o f 40 
mM K-HEPES pH 7.4 in the presence o f varying concentrations o f MSU58 and MSU84 
(0.5 pM to 23 pM) was monitored at 280 nm excitation and 323 nm emission in the 
fluorimeter. The fluorescent signals were corrected for inner filter effect using correction 
factors obtained from the fluorescence o f  0.2 pM  o f tryptophan in 250 pL 40 mM K- 
HEPES pH 7.4 in the presence o f 0.5 pM  to 23 pM  MSU58 and MSU84. The KD was 
determined by fitting the data in KaleidaGraph (Synergy Software, Reading, PA) to the
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equation: (-m 2)/(l+ (m l/m 0)) + m3; where m l=Estim ated KD; m 2=M inimum signal 
value; m3=M aximum signal value
FIQ Correction
In order to correct for the quenching effect o f cleaved DABCYL molecules on the 
total fluorescence o f the product, FIQ correction factors were determined using the 
methods described in [24,25]. Briefly, SNAPtide dilutions were made similar to that used 
in the kinetic assays (2.9 pM  to 50 pM) and the unquenched peptide prepared to a final 
concentration o f 0.5 pM  unquenched peptide in a final volume o f 50 pL. Fluorescent 
endpoint readings o f each SNAPtide concentration in assay buffer (50 pM  to 0 pM  in 50 
pL assay volume, 2:3 fold dilution) and 0.5 pM  o f unquenched peptide in the presence o f 
each SNAPtide concentration were measured after 15 minutes incubation at 25 °C as 
described in the previous section. The endpoint reading o f 0.5 pM  unquenched product 
was m easured total signal o f the unquenched product in the absence o f SNAPtide. The 
experiment was performed in triplicate.
To calculate the correction factors, the signal o f  0.5 pM  unquenched peptide in 
the presence o f SNAPtide was subtracted from the signal o f  each representative 
SNAPtide concentration to obtain the apparent signal o f the 0.5 pM  unquenched peptide 
in the presence o f each SNAPtide concentration. The signal o f  the unquenched peptide in 
the presence o f each SNAPtide concentration was divided by the total signal from the 0.5 
pM  unquenched peptide, to give a ratio o f how much signal reaches the detector in the 
presence o f each SNAPtide concentration. This gave the FIQ correction factor and the
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values can be found in (Table 2). The initial velocities were corrected by dividing with 
the FIQ calculated at each substrate concentration i24\
Turbidimetric Solubility Assay
To investigate the time dependent solubility o f MSU58 and MSU84, a 1:2 fold serial 
dilution o f inhibitors was made to obtain concentrations in the range o f 10 pM  to 40 pM  
in a final volume o f 100 pL in a clear 96 well polypropylene plate. Inhibitor dilutions 
were made with final a DM SO concentration o f 3.2 % to mimic assay conditions with 
control wells containing 3.2 % DMSO in assay buffer. The plate was shaken for 5 
minutes on a plate shaker after which a time course absorbance reading is measured at 
600 nm at 25 °C.
The solubility o f MSU58 and MSU84 in the assay buffer was investigated using the 
procedure described in [26]. Concentrations used were in the range 0.16 pM  to 100 pM  in 
a final volume o f 100 pL in a clear 96 well polypropylene plate by adding 1 pL inhibitor 
to 99 pL assay buffer. Final DMSO concentration was 1 %.
Model discrimination analysis using DynaFit4 software
DynaFit4 software (BioKin Ltd, W atertown, M A) was used to determine the most 
plausible inhibition mechanism. A DynaFit script specifying the fit parameters and 
concentration o f the reactants was prepared for each likely inhibition model 
(Competitive, noncompetitive and uncompetitive). For each model, the catalytic activity 
(&cat) was fixed to the value determined from the kinetic experiments. First order rate 
constants (kon and k0f)  and the second order rate constants in each model were allowed to
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vary as adjustable parameters. The experimental data was then exported to DynaFit and 
analyzed through a non-linear least squares regression.
CHAPTER 3: RESULTS AND DISCUSSION
This study was aimed at identifying the mechanism by which the two quinolinol 
compounds (MSU58 and MSU84) inhibit BoNT/A LC and determining the num ber and 
nature o f  inhibitor binding sites present on the enzyme. The results will benefit structure 
activity relationship (SAR) studies and drug optimization efforts towards the 
development more potent BoNT/A LC inhibitors.
Steady-state kinetics o f BoNT/A LC with SNAPtide support competitive inhibition.
The kinetic parameters (KM, maximum velocity (F max) and £cat) o f BoNT/A LC were 
determined using the substrate analog SNAPtide, a FRET peptide with an FITC 
fluorescent donor on the N-terminus and a DABCYL quencher at the C-terminus. 
BoNT/A LC catalyzes the cleavage o f SNAPtide, releasing the FITC from the DABCYL; 
the resulting increase in fluorescence emission was measured to m onitor product 
formation over time. The fluorescence emission intensities were converted to V0 values 
using standard curves determined in the same experiment. The V0 values were determined 
at multiple SNAPtide concentrations and data was fitted to the M ichaelis-M enten 
equation using GraphPad Prism 6 software (Figure 3).
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[MSU84]= 6 UM 
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FIGURE 3: Effect of inhibitors MSU58 and MSU84 on BoNT/A LC kinetics. BoNT/A LC 
activity was measured in the presence of (•)  0 pM, (■) 3 pM, (A ) 6 pM and (▼) 9 pM MSU58 
(a-c) and MSU84 (d-f) at 490/523nm in a BioteK Synergy HI plate reader. Figures of three 
independent experiments with each inhibitor, conducted in 40 mM K-HEPES containing 0.01% 
Tween 20 at room temperature are illustrated. The V0 values were corrected for FIQ (Results in
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data file: MSU58 data > botox assay 05.23.16.581; botox assay 05.23.16.582; botox assay 
06.14.16.58.1 and MSU84 data > botox assay 04.27.16.84ii; botox assay 04.11.16.84; botox 
assay 08.09.16.84)
A kcat for BoNT/A LC on SNAPtide was determined to be 0.21 s '1 measured at room 
temperature in 40 mM K-HEPES pH 7.4 (Table 1); this value is in qualitative agreement 
with the kcat o f  0.28 s '1 reported previously by Feltrup and Singh at 37 °C in 20 mM 
HEPES, 0.1 % Tween 20 pH 7.6 [24]. The KM we determined (46.4 ± 0.8 pM ) was
approximately twice that determined by Feltrup and Singh (~ 22 pM ); the different 
ranges o f substrate concentrations used in the assays ( 1 - 5 0  pM  here and 1 - 1 0  pM , by 
Feltrup and coworkers, respectively) in addition to the different buffer and Tween 20 
concentrations may be responsible for the difference in K M values. The KM value o f 46.4 
± 0.8 pM  determined here agrees with the value o f  42.3 ± 2.4 reported by Lai and 
coworkers in an excess o f  zinc acetate [21]. In the presence o f 0, 3, 6 and 9 pM  inhibitor 
(Table 1), the V0 versus the SNAPtide concentration curves shifted to the right for both 
inhibitors, indicating an increase in KM with increasing inhibitor concentration (Figure 
3). Presence o f the inhibitor did not significantly affect Fmax. Lineweaker-Burk plots 
(Figure 4) further show an increasing KM and unchanged Vmax with increasing inhibitor 
concentrations. A decrease in the £cat/KM in the presence o f  increasing inhibitor
concentration was observed for both inhibitors (Table 1). These findings are consistent 
with competitive inhibition.
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FIGURE 4: Representative Lineweaver-Burk Plots of the reciprocal of the initial velocity ( 1/V0) 
min/nM versus the reciprocal of the SNAPtide concentration (1/ [SNAPtide] (pM '1)) in the 
presence of varying concentrations of MSU58 (A) and MSU84 (B) (♦) = 0 pM, (■) = 3 pM, (À) 
= 6 pM and (x) = 9 pM. Data was obtained at room temperature in 40 mM K-HEPES pH 7.4 
containing 0.01% Tween 20. Results are representative of three independent experiments (Data 
file: MSU58 data> botox assay 05.23.16.581and MSU84 data> botox assay 04.27.16.84ii). See 
Appendix A3 for full description.
TABLE 1 Kinetic parameters o f the BoNT/A LC catalyzed reaction in the presence o f 
MSU58 and MSU84
[1]
(HM)
Km (hM) Vmax (nM/min) kcat  (s *) kcof/KM (mM-1s-1)
MSU58 MSU84 MSU58 MSU84 MSU58 MSU84 MSU58 MSU84
0 46 ±3 45 ± 11 46 ± 1 58 ±9 0.18 ±0.01 0.23 ±0.04 3.8 ±0.4 5.1 ±2.1
3 47 ±3 55 ±9 44 ±4 57 ±4 0.17 ±0.02 0.23 ±0.02 3.6 ±0.7 4.2 ± 1.1
6 99 ± 13 106 ± 18 54 ±5 73 ±2 0.22 ±0.02 0.29 ±0.01 2.2 ±0.5 2.7 ±0.5
9 104 ±8 94 ±24 48 ±2 57 ±7 0.19 ±0.01 0.23 ±0.03 1.8 ±0.2 2.4 ±0.9
Increasing KM and a constant Emax were observed for both inhibitors and are consistent with
competitive inhibition. &cat values were calculated from the equation Vmax/[ET], where [ET] was 
the enzyme concentration in the assay (4.2 nM). Values are ± S.E for an average of three 
independent experiments.
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Modified FIQ correction for higher SNAPtide concentrations.
It was necessary to correct the data for FIQ, which is the tendency o f  the quencher on the 
intact or cleaved SNAPtide to absorb some o f  the light fluoresced by the FITC in another 
molecule o f a cleaved SNAPtide [24‘25]. This correction had not been reported when the 
previous and only kinetic studies on inhibition mechanism o f a quinolinol compound on 
BoNT/A LC were conducted on QAQ. Feltrup and Singh outlined a correction using the 
slope o f the FIQ correction factors versus SNAPtide concentration [24]. W e used higher 
substrate concentrations than were used by Feltrup et al. At [SNAPtide] > 10 or 15 pM , 
the FIQ correction factors versus the SNAPtide concentration relationship was not linear 
(Figure 5) and we were not able to use the slope to correct our data. Consequently, we 
calculated the correction factors (Table 2) as outlined by Liu et al.[25]. The uncorrected 
Km  (17.8 ± 1 .6  pM ) was 2.6-fold lower than the FIQ-corrected KM (46.4 ± 0.8 pM) 
(Figure 6). The correction also resulted in a 2.3 times higher £cat value o f  0.21 ± 0.02 s '1 
compared to 0.09 ± 0.01 s '1 (uncorrected £cat). Feltrup and Singh reported a 1.96-fold and 
2.12-fold increase in the KM and kcat respectively, as a result o f  the FIQ correction, in 
agreement with the results here.[24] The FIQ correction is necessary when using 
SNAPtide as the substrate to study BoNT/A LC kinetics but the slope cannot be applied 
when concentrations o f substrate in excess o f 20 pM  are used. A previously described 
FIQ correction was employed and found to significantly affect value o f kinetic 
parameters [24"25].
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[SNAPtide] (nM)
FIGURE 5: FIQ correction factors versus SNAPtide concentration are shown. The FIQ 
correction factors were calculated as described by Feltrup and Singh. The relationship is linear up 
to 10 - 15 pM but not linear at concentrations > 20 pM. The experiment was performed at room 
temperature using 40 mM K-HEPES at pH 7.4. (Data file: FIQ factors > FIQ factors 08.09.16).
TABLE 2: FIQ correction factors
[SNAPtide] OiM) FIQ correction 
factors
50.0 0.56 ± 0.009
33.3 0.67 ± 0.026
22.2 0.69 ± 0 .015
14.8 0.70 ± 0 .049
9.9 0.82 ± 0 .008
6.6 0.94 ± 0.044
4.4 0.92 ± 0 .017
2.9 0.93 ± 0 .033
0.0 1.0
Fluorescent Internal Quenching correction factors determined for correcting the initial velocities 
at the substrate concentrations used in the assay. Calculated factors are an average of three 
experiments conducted at room temperature in 40 mM K-HEPES containing 0.01% Tween 20 at 
pH 7.4. (Data file: > FIQ factors > FIQ factors 08.09.16).
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FIGURE 6: The change in KM (Figure A) and kcaX (Figure B) before and after FIQ correction in 
the presence of different concentrations of MSU58. FIQ correction factors were determined at 
conditions similar to the assay conditions. Values are the averages of three independent 
experiments with S.E. (Data file: >MSU58 data > botox assay 06.14.16.58.1)
Kj and KD ofMSU58 and MSU84 with BoNT/A LC
The IC50 values for MSU58 and MSU84 were determined to be 3.3 ±  0.3 pM  and 5.8 ± 2 
pM  (±S.E, N  = 14, 4) respectively, using [S] o f 0.625 pM  (Figure A1 in Appendix). A 
decrease in percent inhibition at concentrations >10 pM  was observed for MSU84 and 
was found to be due to a time-dependent precipitation o f MSU84 at concentrations >10 
pM  (Figure A2(b) in Appendix). The better inhibition by MSU58 compared to MSU84 
may be due to the 3-pyridyl substituent in MSU58. Structure activity relationship studies 
by Caglic and coworkers reported that a 3-pyridyl substituent at R2 resulted in a 60 % 
more potent inhibitor against BoNT/A LC. Docking studies revealed a hydrogen bond 
between the 3-pyridyl substituent and the amino group o f Arg363 [4>17]. Interaction with 
Arg363 is also important for stabilizing the binding o f the substrate for catalysis [2], 
Caglic and coworkers also suggested that a methyl substituent at the R4 position o f the
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quinolinol moiety may account for 85 % increased inhibitory activity; introduction o f a 
methyl group at R4 o f MSU58 and M SU84 could be explored in future studies [17].
The Kj o f each inhibitor was obtained by converting the IC50 to Kj using the 
Cheng-Prusoff equation (See Table 3 caption) and also by employing Dixon plots [23]. 
The Kx values calculated for MSU58 and MSU84 were 3.3 ± 1.1 pM  and 5.7 ± 4.6 pM , 
respectively (Table 3). As expected, Kj was similar to the IC50 because the [SNAPtide] 
used in the screening o f the inhibitors was «  KM [27, 28]. In the Dixon plots, the 
reciprocals o f the V0 from the kinetic analysis were plotted against the inhibitor 
concentrations (Figure 7). Data at each substrate concentration was fitted individually to 
a linear equation and the negative X-axis value o f the point o f intersection o f the lines in 
the upper left quadrant gave an estimate o f  the Kj. For each Dixon plot, the negative X- 
axis value o f  the intersection point o f  all pairs o f individual lines were determined and the 
average o f these values was used to obtain the Kj o f 3.2 ± 0.5 pM  for M SU58 and 6.2 ± 
0.9 pM  for MSU84. These values correspond to those determined using the Cheng- 
Prusoff equation (Table 3) and indicate that both compounds inhibit BoNT/A LC 
protease activity in the single digit m icromolar range, with MSU58 having a slightly 
higher inhibitory effect compared to MSU84. It can also be seen in Figure 7 that the lines 
intersect in the second quadrant above the negative X-axis, supporting competitive 
enzyme inhibition model for each inhibitor [29]. A  KD o f 1.9 ± 0.5 pM  and 7.5 ± 1.1 pM
was determined for MSU58 and MSU84 respectively. These values are similar to the KT 
o f 3.2 ± 0.5 pM  for MSU58 and 6.2 ± 0.9 pM  for MSU84 and agree with competitive 
inhibition. Representative KD curves for MSU58 and MSU84 are illustrated in Figure 8.
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FIGURE 7: Dixon Plots of MSU58 (a-c) and MSU84 (d-f) with Kj values. Figures represent 
three independent experiments with each inhibitor, performed at room temperature in 40 mM K- 
HEPES pH 7.4, containing 0.01 % Tween 20. l/V0min/nM was plotted against the concentration 
of the inhibitor for varying the SNAPtide (2.9 pM -  50.0 pM). (Data file: MSU58 data: botox 
assay 05.23.16.581; botox assay 05.23.16.582; botox assay 06.14.16.58.1 and MSU84 data: botox 
assay 04.27.16.84ii; botox assay 04.11.16.84; botox assay 08.09.16.84)
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TA BLE 3: The IC50 values and Kj o f MSU58 and MSU84
Inhibitor IC50 (HM) Ki (nM)
Dixon plot Cheng-Prusoff
equation
MSU58 3.3 ±0.3 (14) 3.2 ±0.5 (3) 3.3 ± 1.1 (14)
MSU84 5.8 ± 2.3 (4) 6.2 ±0.9 (3) 5.7 ±4.6 (4)
The Kr was determined from Dixon plots and related to the Kj value determined from the Cheng-
Prusoff equation using predetermined IC50 values of each compound. Cheng-Prusoff equation is 
given by; IC50 = Kr (1+ [S]/KM) [23]. Values are ± S.E (N).
A
20
BFIGURE 8: Representative KD curves for MSU58 (A) and MSU84 (B). The fluorescent 
signalwas plotted against the concentration of each inhibitor and fitted to the equation: (- 
m2)/(l+(ml/m0)) + m3 in KaleidaGraph. The experiment was conducted in 40 mM K-HEPES 
pH7.4 at room temperature. Results are representative of three independent experiments (Data 
file: > Kd expts > BoNT A LC 58 trial 2 12.02.16 and >BoNT A LC 84 trial 3 12.02.16).
Model Discrimination Analysis
To determine whether the noncompetitive and uncompetitive inhibition mechanisms 
could be reasonably ruled out for MSU58 and M SU84, model discrimination analysis 
was performed. The model discrimination function in the DynaFit software uses 
statistical methods to determine the most probable inhibition model among a set o f 
models [30]. The Akaike information criterion (AIC) was used; the model with the lowest 
AIC num ber is defined as the best model [30]. DynaFit was used to calculate the 
difference between the AIC numbers o f each model and the best model (AAIC) and to 
determine the Akaike weights w(AIC) [30'31]. The most plausible model has the highest
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w(AIC) with 1.0 being the maximum possible w(AIC) value [31]. Results o f  model 
discrimination analysis in Table 4 shows w(AIC) for both MSU58 and M SU84 to be 1.00 
for the competitive model o f inhibition and 0.00 for either noncompetitive or 
uncompetitive inhibition, indicating that the competitive model o f inhibition is the most 
likely mechanism o f inhibition o f BoNT/A LC by either MSU58 and MSU84 and that the 
other models may be ruled out. This is consistent with results from Table 1, the 
Lineweaver-Burk plots (Figure 4) and the Dixon plots in Figure 7.
TABLE 4: Results o f model discrimination analysis using DynaFit
(I)
Model np AAIC
MSU58 MSU84
Competitive 36 0.00 0.00 0.00 0.00 0.00 0.00
Uncompetitive 35 1217.7 1002.4 1094 286.1 1304.7 542.1
Noncompetitive 36 108.8 23.2 2550.8 1665.7 1163.7 1693.4
Model np Akaike weight (w(AIC))
MSU58 MSU84
Competitive 36 1.00 1.00 1.00 1.00 1.00 1.00
Uncompetitive 35 0.00 0.00 0.00 0.00 0.00 0.00
Noncompetitive 36 0.00 0.00 0.00 0.00 0.00 0.00
Table 4 is split into (I) and (II). The AAIC of the best model is equal to 0.00; w(AIC) for the 
competitive mtaodel = 1.00 supports the finding that both MSU58 and MSU84 are competitive 
inhibitors of BoNT/A LC.
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Kinetic rate constants
DynaFit was used to perform a non-linear regression analysis to determine the kinetic 
rate constants associated with the BoNT/A LC catalyzed reaction by fitting the 
experimental data to a least squares fit o f the mechanism shown in Scheme 1 [30]. Table 5 
displays the average best fit association and dissociation rate constants (£on and £off) 
values and inhibitor association and dissociation rate constants (kai and kd o f  three 
independent experiments with compounds MSU58 and MSU84. The constants ka {and 
&d i are on the same timescale as the catalytic activity and these compounds do not exhibit 
time-dependent inhibition. The kcai value was fixed to the experimentally determined
value 0.21 s '1. The kon and &off (Table 5) are related to the KM and kcat (KM =
kon
the calculated KM is 43.3 ± 8.2 pM; this value is close to the value o f  46.4 ± 0.8 pM  
determined from fitting the data to the M ichaelis-M enten equation. Table 5 also shows 
average values o f the ka i and kd i? which are related to Kj (Kx = kdA/kai). These values 
were calculated to be 6.2 ± 1.3 pM  for MSU58 and 5.0 ± 1.4 pM  for MSU84.
E + S
+
I
E.l
E + P
SCHEME 1: The competitive mechanistic model by which MSU58 and MSU84 inhibit BoNT/A 
LC.
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TA BLE 5: DynaFit determined rate constants and kinetic constants
Inhibitor kon ( p M 1 s 1) ¿offO*'1) K m (HM) ¿a.i ( p M 1 s '1) *d.i (s ') ^  (pM )
MSU58 0.04 ± 0.003 2.0 ±0 .1 55 ± 7 0.13 ± 0 .01 0.8 ± 0 .1 6.2 ± 1.3
MSU84 0.06 ±0.01 1.7 ± 0 .4 32 ± 12 0.14 ± 0 .0 2 0.7 ±0 .1 5.0 ± 1.4
DynaFit determined rate constants and determined kinetic constants; values are averages of three 
independent data ± S.E. The experimental data were fit to the model in Scheme 1 and the kcat was 
fixed to 0.21 s'*. The KM and Kj values in the table were calculated from the on and off rate 
constants and agree with the experimentally found values.
Time-dependent Precipitation o f MSU84
A phenomenon that was observed during the determination o f IC50 values for MSU58 
and MSU84, was the markedly decrease in percent inhibition at higher concentration o f 
the compound following an expected increase in percent inhibition with increasing 
concentration o f MSU84 (Figure 9). This effect was not observed for MSU58. To 
investigate this phenomenon, a turbidimetric assay was performed as described under the 
methods and materials section. The time dependence o f solubility was monitored at A6oo 
nm (absorbance) over 4 hours under assay conditions. The results, displayed in Figure 
9(b), revealed that MSU84 begins to precipitate out o f solution with time at higher 
concentrations (20 pM  and 40 pM). At these concentrations, the compound molecules 
begin to cluster and aggregate, increasing the turbidity o f the solution and may be the 
underlying reason for the observed decrease in percent inhibition at those concentrations 
o f MSU84. To ensure that precipitation did not impact inhibition mechanism studies, the 
concentrations o f MSU84 used in the kinetic assay were kept below 20 pM. The 
solubility assay also revealed that M SU84 was not soluble beyond 20 pM  whereas no 
solubility issues were observed for MSU58 up to 100 pM  (Figure 10).
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a b
Time (min)
FIGURE 9: Time-dependent precipitation of MSU84. Turbidity reaction monitored for (a) 
MSU58 and (b) MSU84. □ = 10 pM and 0 = 40 pM. The absorbance was measured at 600 nm for 
4 hours with a 3.2 % final DMSO concentration. Figures represent absorbance values at the 
highest concentration (40 pM) and the concentration closest to that used in the kinetic assay (10 
pM). Error bars are the Standard errors of the average of two experiments. (Data file: > Solubility 
> Timecourse Turbidity assay 6.28.16)
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FIGURE 10: Solubility of MSU58 and MSU84. The solubility of MSU58 (♦) and MSU84(b) in 
the assay buffer (40 mM K-HEPES pH 7.4) at room temperature. The figure is the average of 
three independent experiments with standard errors. (Data file: > Solubility > Solubility 11.30.16 
plate 3)
25
CONCLUSION
M any reports suggest that quinolinol based compounds block the BoNT/A LC active site 
via metal chelation by the 8-hydroxy quinolinol moiety but not previously supported by 
kinetic experiments. Conversely, noncompetitive inhibition by quinolinol compound 
QAQ was reported based on kinetic studies [21], Others have suggested that quinolinol 
compounds do not inhibit BoNT/A LC by excluding the interaction o f the zinc with 
water, which is necessary for substrate cleavage [4]. MSU58 and M SU84 were found to 
be competitive inhibitors o f BoNT/A LC. We found that it was necessary to do the FIQ 
correction when determining the kinetic parameters using SNAPtide and that the non­
linearity o f  the relationship between the correction factors and SNAPtide concentrations 
beyond 20 pM  SNAPtide requires that the FIQ factors be determined as suggested by Liu 
et al., and as we have done here when using higher SNAPtide concentrations that are 
required for full Michaelis -Menten analysis. It was determined that the phenomenon 
where MSU84 gives a lower percent inhibition at the highest concentration in the 
screening assay was due to the slow precipitation o f this compound at concentrations o f 
20 and 40 pM. This study is the first to report experimental data demonstrating 
competitive inhibition o f  BoNT/A LC by a quinolinol compound. In future SAR studies 
and drug optimization efforts, the addition o f a methyl group to the R4 position o f the 
quinolinol m oiety in MSU58 and MSU84 may yield more potent BoNT/A LC inhibitors.
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APPENDIX
Al: Determination o f IC$g
Inhibitor stock solutions were made in DMSO at 10 mM concentration and diluted to 
make a 1 mM solution in DMSO for the assay. Serial dilutions o f the inhibitor (1:2 fold) 
were made in DMSO in clear polypropylene plates and transferred to the ha lf area black 
well plates to obtain concentrations in the range o f 1.6 pM  to 20 pM  in a final well 
volume o f 50 pL. Each assay well also contained 4.2 nM BoNT/A LC and 0.625 pM  
SNAPtide and a final DMSO concentration in the assay o f 2 %. Experiments were 
conducted a minimum o f four independent experiments in the BioTek Synergy 2 for 90 
minutes; set at 485 nm excitation and 528 nm emission with 5 minutes shaking between 
reads. The percent inhibition versus compound concentration graphs were used to 
determine the IC50 values in M icrosoft Excel using the Solver function and the four- 
parameter logistic equation [32] (Figure A l ) .
FIGURE Al: Representative dose-response curves for determining the IC50 of compounds 
MSU58 and MSU84. The curves were fit to a four parameter logistic equation using the solver 
function in Microsoft Excel [32]. The curve fitting for MSU84 was done not including the 20 pM 
data point. The experiments were performed in 40 mM K-HEPES pH 7.4 at room temperature.
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A2: Lineweaver-Burk analysis supports competitive inhibition
Double reciprocal plots (Lineweaver-Burk plots) were created in M icrosoft Excel (Figure 
4). The points o f intersection on the positive y-axis and negative x-axis represent the 
reciprocals o f the Vmax (1 / Vmax) and KM (1/ KM), respectively. The point o f  intersection 
on the y-axis did not change in the presence o f increasing inhibitor, indicating that the 
Vmax ° f  reaction was independent o f inhibitor concentration for both MSU58 and 
MSU84. On the other hand, the points o f intersection on the negative X-axis change with 
inhibitor concentration, corresponding to an increasing KM with an increase in the 
concentration o f inhibitor. This is characteristic o f the competitive mechanism o f 
inhibition and agrees with the trend observed in Table 1, suggesting that both MSU58 
and M SU84 compete with SNAPtide for the active site o f BoNT/A LC. This agrees with 
the earlier docking studies that suggested that quinolinol compounds interact with the 
zinc cation in the hydrophobic pocket o f the active site o f BoNT/A LC [4> 17].
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FIGURE A2: Representative DynaFit traces for the competitive inhibition model for MSU58 and 
MSU84. Figures are a graph of the fluorescent signal versus the time (s) for data sets obtained 
from three independent experiments.
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A3: Compound synthesis
M SU58. A mixture o f 4-fluorobenzaldehyde (0.11 ml, 1 mmol) and 3-aminopyridine (94 
mg, 1 mmol) was stirred in a 50 ml RBF for 30 min before adding 5-chloro-8-quinolinol 
(144 mg, 0.8 mmol). The mixture was heated to 120 °C whereupon the reaction became 
homogenous after approximately 1 hour; stirring continued for another 6 hours at 120 °C. 
After TLC indicated that the quinolinol was consumed, the flask was cooled. The 
contents were dissolved in minimum amount o f methylene chloride and loaded on a silica 
gel column. Chromatography was performed using 30% ethyl acetate in hexanes. The 
desired product was obtained in 56% yield and greater than 97 % purity.
'H  NM R (300 MHz, CDCb): 8 8.81-8.83 (dd, 1H), 8.46-8.50 (dd, 1H), 8.17-8.18 (d, 1H), 
7.94-7.96 (dd, 1H), 7.63 (s, 1H), 7.53-7.58 (m, 1H), 7.43-7.48 (m, 2H), 7.01-7.10 (m,
3H), 6.90-6.94 (m, 1H), 6.07-6.09 (d, 1H).
M SU84. A mixture o f 3-fluorobenzaldéhyde (0.11 ml, 1 mmol) and benzene 
sulfonamide (157 mg, 1 mmol) was stirred in a 50 ml RBF for 30 min and was added 5- 
chloro-8-quinolinol (144 mg, 0.8 mmol). The mixture was heated to 120 °C whereupon 
the reaction became homogenous after approximately 1 hour; stirring continued for 
another 6 hours at 120 °C. After TLC indicated that the quinolinol was consumed, the 
flask was cooled. The contents were dissolved in minimum amount o f  methylene 
chloride and loaded on a silica gel column. Chromatography was performed using 30% 
ethyl acetate in hexanes. The product was obtained in 53% yield and greater than 96 % 
purity.
'H  NM R (300 MHz, CDCb): 8 8.76-8.78 (dd, 1H), 8.40-8.44 (dd, 1H), 7.62-7.65 (m,
2H), 7.53-7.57 (dd, 1H), 7.25 (s, 1H), 7.24 (s, 1H), 7.06-7.14 (m, 3H), 6.89-7.00 (m, 2H),
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6.02-6.05 (d, 1H), 5.78-5.81 (d, 1H). Compound M SU 58 was synthesized to greater than 
97 % purity.
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